ACC

Medicare beneficiaries who received an implantable pulmonary artery pressure (PAP) sensor had a statistically significant 45 percent lower rate of heart failure hospitalizations and reduced costs at six months, according to a retrospective cohort study.

Older adults with atrial fibrillation who underwent left atrial appendage occlusion (LAAO) at the time of cardiac surgery had an approximately 40 percent reduction in thromboembolism and a 15 percent reduction in all-cause mortality, according to a database analysis.

On the final day of this year’s American College of Cardiology (ACC) conference, Mary Norine Walsh, MD, assumed her role as the president of the organization.

Findings presented at the American College of Cardiology’s 66th Annual Scientific Session show that adding a cholesterol-lowering drug to treatment with a statin has no effect on cognition and thinking.

New research looking at the efficacy of rivaroxaban, an oral blood-thinning medication compared to aspirin yielded positive results for the complex drug, showing that it can limit the recurrence of a venous thromboembolism (VTE) without increasing the risk for bleeding.

Subclinical leaflet thrombosis occurred in 13.6 percent of patients undergoing transcatheter aortic valve replacement (TAVR) and 3.8 percent of patients undergoing surgical aortic valve replacement (SAVR), according to an analysis of two registries.

Research from the University of Louisville has found that the Abiomed Impella 2.5 heart pump helps reduce the risk of acute kidney injury—even in patients with preexisting kidney disease—when physicians are trying to complete a high-risk percutaneous coronary intervention (HRPCI).

A randomized study found that using two FDA-approved cerebral embolic protection devices in patients undergoing surgical aortic valve replacement (SAVR) was not associated with an improvement in freedom from clinical or radiographic infarction or clinical stroke.

At 12 months, patients with stable angina or acute coronary syndrome had similar rates of major adverse cardiac events whether they underwent revascularization guided by instantaneous wave-free ratio (iFR) or fractional flow reserve (FFR), according to a randomized, registry-based trial.

A coalition of medical centers in southeast Michigan have found a way to increase the survival rate of cardiogenic shock patients to 84 percent by using a heart pump manufactured by Danvers, Massachusetts-based Abiomed. 

Patients with chronic total occlusions (CTOs) had similar results whether they underwent PCIs or received optimal medical treatment, according to a prospective, open-label, randomized trial.

Patients with hypertension who received an electronic counseling intervention had a 10.1 mmHg reduction in systolic blood pressure after a year compared with a six mmHg reduction for a control group, according to a randomized, double-blind controlled trial in Canada.